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match and type was: 5 or 6/6 HLA-matched related donors
(n267), 5 or 6/6 matched unrelated donors (n171). The median
day of onset of GVHD grade 2-4 for related donors was 30d and
for unrelated donors was 20d.
We expressed the day 7 value as a ratio to pre-transplant baseline.
The mean day 7 TNFR1 ratios strongly correlate with severity of
GVHD: 1.9 (GVHD 0-1, n269), 2.3 (GVHD 2, n83), and 2.9
(GVHD 3-4, n86), p0.001.
When treated as a continuous variable, day 7 TNFR1 ratios
strongly correlated with both the likelihood of GVHD 2-4
(p0.001) and 1yr TRM (p0.001). Patients with a day 7 TNFR1
ratio above 2.5 (approximately the mean ratio for patients with
GVHD 2-4), were much more likely to experience GVHD and die
within the ﬁrst year from TRM, independent of donor source
[Table 1].
Recipient DNA samples were available for 222 subjects who were
similar to the entire cohort with respect to age, donor type, degree
of match, conditioning regimen, TNFR1 ratios and incidence of
GVHD 2-4. Sixteen single nucleotide polymorphisms (SNPs)
known to have functional relevance for the TNF axis (TNF-,
TNFRSF1A (encoding TNFR1), and TNFRSF1B (encoding
TNFR2)) were analyzed. One SNP (TNFRSF1B 1690 T/C) was
found to have a statistically signiﬁcant association with the day 7
TNFR1 ratio (2.2 vs 1.8, p  0.04) and probability of GVHD 2-4,
after adjustment for the TNFR1 ratio (45% vs 22%; p  0.02). In
conclusion, we have observed a clinically important relationship
between genetic polymorphisms and post-transplant expression of
TNF pathway proteins. Improved understanding of this relation-
ship may allow for a risk-adjusted approach to GVHD prevention.
Table 1
TNFR1 ratio - All patients (n438) GVHD 2-4 1y TRM
TNFR1 ratio <2.5 (n328) 32% 17%
TNFR1 ratio >2.5 (n110) 58% 39%
p<0.001 p<0.001
TNFR1 ratio - related donors (n267)
TNFR1 ratio <2.5 (n210) 26% 11%
TNFR1 ratio >2.5 (n57) 50% 29%
p<0.001 p0.007
TNFR1 ratio - unrelated donors (n171)
TNFR1 ratio <2.5 (n118) 43% 28%
TNFR1 ratio >2.5 (n53) 65% 49%
p0.001 p0.01
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SHELF” IMMUNOTHERAPY
Lowdell, M.W.1, North, J.1, Bakhsh, I.1, Marden, C.1, Anderson, R.1,
Pittman, H.1, Mackinnon, S.1 1Department of Haematology, Royal Free
& UCL Medical School, London, United Kingdom.
Resting human NK cells can be primed to lyse NK–resistant
tumor cells by pre-incubation with lysates of the leukemic cell line
CTV-1. The primed NK cells demonstrate tumor-restricted lysis
in vitro. NK cells isolated from normal healthy donors and co-
incubated with irradiated CTV-1 lysates synthesized CD69 within
60 min with maximal expression achieved within 6 hr. The tumor-
activated NK cells (T-ANKs) lysed NK resistant RAJI and Daudi
cells in a 4-hour assay. The degree of lysis was equivalent to that of
matched lymphokine activated killer cells (LAK) after non-speciﬁc
activation with IL-2. CTV-1 cells are HLA-C type 2 homozygous
and express HLA-Bw4 alleles. They thus can ligate KIR2DL1
(CD158a) and KIR3DL1 (CD158e1) on NK cells. Co-cultures of
HLA-matched or mis-matched NK with CTV-1 showed there was
no signiﬁcant difference in the generation of T-ANK activity in
the presence or absence of KIR ligation. T-ANK cells from allo-
geneic donors were capable of lysis of primary AML cells of all
FAB types, primary CML blasts, the relatively NK-resistant breast
cancer cell line, MCF-7, and primary tumor cells isolated from
resected tissue from patients with breast cancer and ascities from
patients with ovarian cancer. T-ANK cells from ﬁve AML patients
in CR consistently induced signiﬁcantly greater lysis of autologous
AML blasts than the matched NK cells (p0.05). Allogeneic T-
ANK cells were compared with NK cells from the same donor with
respect to lysis of normal autologous and allogeneic PBMC. Nei-
ther NK nor T-ANK cells lysed autologous PBMC nor did they
lyse PBMC from HLA-C mismatched normal donors. To deter-
mine the likelihood of bone marrow suppression by T-ANK cells
we established hematopoietic colony forming assays with bone
marrow from 5 normal donors and added T-ANK from HLA-C
mismatched donors at increasing ratios. CFU-GM, BFU-E and
CFU-GEMM were not affected by co-incubation with HLA-mis-
matched T-ANK even at effector:target ratios of 20:1. Further-
more, pooled TaNK generated from multiple donors showed
equivalent in vitro activity to that of single donor products.We
believe that this demonstrates a two stage process for NK activa-
tion; priming and triggering, the ligands for which are distinct.
Tumor priming of NK primes cells capable of lysing a broad
spectrum of NK-resistant tumors irrespective of KIR ligation.
They are readily generated to clinical-grade and may represent an
“off-the-shelf” immunotherapy product.
32
SINGLE VERSUS DOUBLE UMBILICAL CORD BLOOD TRANSPLANTA-
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Transplantation of 2 partially HLA matched UCB units has been
shown to be a safe and effective means to overcome the cell-dose
barrier in adolescents and adults. In addition, preliminary data
suggest that double UCBT is associated with a greater graft-
versus-leukemia effect (Blood 2005:106:93a). To date, there has
been no comparative analysis on the risk of acute GVHD in this
population of patients. Therefore, we compared rates of acute
GVHD in recipients of single (n210) versus double (n169)
UCBT. Double UCB recipients were more likely to be older,
transplanted in recent years, treated with a non myeloablative
therapy, received mycophenolate mofetil as GVHD prophylaxis,
and less likely to receive antithymocyte globulin (ATG) as part of
the conditioning. Incidences of grades II-IV and III-IV acute
GVHD were higher in recipients of double than single UCBT
recipients (60% vs 33%, p.01) and (21% vs 11%, p.01), respec-
tively. Adjusting for differences between groups, two factors were
associated with the development of grade II-IV acute GVHD in
Cox regression: use of 2 UCB units (RR 2.0 vs 1.0 [95% CI,
1.3-3.2, p.01]) and absence of ATG in the preparative regimen (RR
1.0 vs 0.5 [95% CI, 0.3-0.8, p.01]). Other factors that were tested
in the model but not determined to be signiﬁcantly associated with
acute GVHD were recipient age, gender, weight, diagnosis, time
from diagnosis to UCBT, HLA disparity, total and CD3 cell dose,
CMV serostatus, conditioning regimen, and GVHD prophylaxis.
Despite increased risk of acute GVHD, TRM 1 year was signiﬁ-
cantly lower in recipients of double UCBT (17%, 95% CI, 5-29%)
as compared to recipients of a single UCBT (47%, 95% CI,
26-68%; p .02) among those that developed grade III-IV acute
GVHD. Survival at 1 year among those with grade III-IV acute
GVHD was signiﬁcantly higher after double UCBT (67%, 95%
CI, 51-83%) than after single UCBT (41%, 95% CI 21-61%;
p.04). In conclusion, risk of acute GVHD is signiﬁcantly higher
in recipients of two partially HLA matched UCB units, yet it does
not appear to adversely effect TRM or survival. ATG in the
preparative therapy, however, does not appear to reduce TRM
despite its favorable association with reduced GVHD. Impact of
GVHD on immune recovery and infection risk in recipients of
single and double UCBT is under investigation.
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